Nebilet (Nebivolol)

Nebivolol blocks β1‑adrenergic receptors in the heart, decreasing heart rate and contractility, which lowers blood pressure. It also stimulates endothelial nitric‑oxide synthase, causing nitric‑oxide‑mediated vasodilation that further reduces peripheral vascular resistance and supports heart‑failure management.

The dose of Nebilet is individualized by a qualified prescriber based on the patient’s clinical condition, age, renal and hepatic function, and response to therapy. Physicians typically start with a low dose and titrate as needed, following current clinical guidelines.

Safety data for nebivolol in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and alternative therapies are preferred when possible.

To order Nebilet, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Nebilet (nebivolol) is a third‑generation β1‑selective blocker with additional nitric‑oxide‑mediated vasodilatory properties, which may result in fewer metabolic side effects compared with older non‑selective beta‑blockers. Its dual action can provide effective blood‑pressure control while offering potential benefits in endothelial function.

Nebilet tablets should be stored at ambient temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged.

Nebilet is taken orally, usually once daily, with or without food, as directed by the prescribing clinician. Swallow the tablet whole with a glass of water; do not crush or chew unless specifically instructed.

Serious adverse events include severe bradycardia, symptomatic hypotension, bronchospasm in patients with reactive airway disease, and rare cases of heart block or allergic reactions such as angioedema. Patients should seek immediate medical attention if they experience fainting, rapid weight gain, or difficulty breathing.

Nebilet is contraindicated in patients with known hypersensitivity to nebivolol or any excipients, in those with severe bradycardia, second‑ or third‑degree atrioventricular block without a pacemaker, and in individuals with uncompensated heart failure or severe hepatic impairment. Caution is also advised for patients with asthma or chronic obstructive pulmonary disease.